ArticleFrontiers in public health2025
Trends in prevalence and disability-adjusted life years for refractive disorders in China and globally from 1990 to 2021: an analysis of the Global Burden of Disease Study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to describe the temporal trends in the prevalence and disability-adjusted life years (DALYs) of refractive disorders (RD) in China and globally from 1990 to 2021 and provide predictions in China for the next decade. Methods: Utilizing open data from the Global Burden of Disease database (2021), this study conducted a comprehensive comparative analysis of the RD burden in China and globally, including changes in prevalence and DALYs. Joinpoint regression was employed to calculate the annual percentage change, the average annual percentage change, and its corresponding 95% confidence interval to reflect segmented trends in RD burden. The APC model was used to assess the net effects of age, period, and cohort. The ARIMA model was applied to predict future trends. Results: The temporal trend of the health burden of RD in China aligned with the global trend, though the magnitude of change was greater, and the gap between the two had been narrowing recently. In China, the age-standardized DALYs rate for the total population (per 100,000 population) decreased from 74 in 1990 to 66 in 2021 and was projected to fall to 29.43 by 2031. The age-standardized prevalence rate for the total population (per 100,000 population) was expected to decrease to 411.23 by 2031, down from 1568 in 1990 to 1468 in 2021. However, the number of cases and the crude rates of prevalence and DALYs exhibited upward trends. In terms of age-specific rates, older adults exhibited higher prevalence and DALYs rates than younger adults. Regarding gender stratification, females had higher prevalence and DALYs rates than males. Conclusion: The age-standardized rates of prevalence and DALYs for RD have decreased in recent years and may continue to decline over the next decade. However, the crude rates of prevalence and DALYs are on the rise. The health burden of RD remains substantial, with females and the older population bearing a higher burden than males and younger populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.